US › Healthcare

Citius Pharmaceuticals Inc (CTXR)

US · Healthcare · Biotechnology

$0.460.00%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$1.5M

Net profit

$-8.9M

EPS

$-0.34

EPS estimate

$-0.36

Net margin

-593.3%

EPS came in at -0.34 against a street estimate of -0.36 — a beat of 5.6%.

Key statistics

Market cap

$12.8M

Forward P/E

0.3

P/B

0.24

Book value

$2.43

EPS (TTM)

$-1.75

52-week high

$2.19

52-week low

$0.45

50-day MA

$0.59

200-day MA

$0.68

Beta

1.00

Analyst view

Analysts rate Citius Pharmaceuticals Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $4.00.

Shareholding

Insiders

1.80%

Institutions

4.95%

Largest institutional holders

Fund	Stake
Geode Capital Management, LLC	0.79%
Vanguard Capital Management, LLC	0.72%
Miller Financial Services LLC	0.47%
Citadel Advisors Llc	0.46%
Jane Street Group LLC	0.45%
Vanguard Fiduciary Trust Co	0.28%
BlackRock Inc	0.25%
Northern Trust Corp	0.23%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Citius Pharmaceuticals Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.